Oncogene licenses cancer detection technology to Bayer for inclusion on Technicon Immuno 1 analyzer.
This article was originally published in The Gray Sheet
Executive Summary
ONCOGENE SCIENCE CANCER DIAGNOSTIC R&D DEAL WITH BAYER provides a fully automated serum-based analyzer, Bayer's Technicon Immuno 1, for Oncogene's in vitro cancer detection technology. The deal replaces a development pact with Becton Dickinson that had been in place since 1984. In September, Oncogene chose not to renew the deal with BD because the firm does not offer an automated immunoassay system.